Skip to main content

Table 4 BCRF-survival in subgroups of patients according to pre- and postoperative ADT receivers and non-receivers and their postoperative ADT-response

From: Cancer-specific and overall survival in patients with recurrent prostate cancer who underwent salvage extended pelvic lymph node dissection

  Without ADT after surgery With ADT after surgery
Patients without preoperative ADT, n = 9 (20 %) Total without / with ADT 3 (33.3 %) 6 (66.7 %)
Of the above: BCRF-survival after salvage ePLND, n (%) 2 of 3
(66.7 %)
5 of 6
(83.3 %)
Duration of BCRF-survival after salvage ePLND (months):
1. mean duration ± SD
18 ± 3 33.4 ± 15.8
2. median duration 18 36
3. min-max duration 15–21 6–53
Patients with preoperative ADT n = 36 (80 %) Total without / with ADT 2 (5.6 %) 34 (94.4 %)
Of the above: BCRF-survival after salvage ePLND, n (%) 2 of 2
(100 %)
24 of 34
(70.6 %)
Duration of BCRF-survival after salvage ePLND (months):
1. mean duration ± SD
54.5 ± 5.5 30.1 ± 25.2
2. median duration 51.75 23.5
3. min-max duration 49–60 4–93